Medical Billing · Nationwide
Pediatric Vascular Malformations, Hemangiomas & Sclerotherapy Medical Billing Services
Image-guided percutaneous sclerotherapy for low-flow venous and lymphatic malformations (LM/VM), transcatheter embolization for high-flow arteriovenous malformations (AVM), fluoroscopic/ultrasound guidance (+76937/+77002), off-label sclerosant J-code compliance (bleomycin, doxycycline, sodium tetradecyl sulfate), staged session Modifier -58, and general anesthesia concurrency.
Aethera Healthcare Solutions provides full-service medical billing and revenue cycle management to pediatric interventional radiologists, pediatric vascular anomaly specialists, plastic surgeons, and multidisciplinary vascular anomaly centers across the United States. We handle coding, claims, payment posting, denial management, and A/R follow-up end to end — so your team can stay focused on patient care while your revenue cycle runs cleanly.
Typical pediatric vascular malformations, hemangiomas & sclerotherapy CPT range we work: 37241, 49185, 37242, 36245, 36224, 76937, 77002, 99214, 99223, J0800, J9040.
Why pediatric vascular malformations, hemangiomas & sclerotherapy billing leaks revenue
Sclerosant drug J-code denials: Commercial payers rejecting unclassified or off-label sclerosing agents (e.g. bleomycin J9040, doxycycline J3490, sodium tetradecyl sulfate J3490) citing investigational non-coverage policies
Percutaneous sclerotherapy (37241/49185) downcoding: Inappropriate downcoding of complex multi-cystic vascular malformation ablation to simple soft tissue aspiration or cyst injection
Ultrasound and fluoroscopic guidance bundling: Denials of imaging guidance codes (+76937-26 and +77002-26) as inclusive to vascular embolization or sclerotherapy
Staged sclerotherapy session global recoupments: Frequent denials of second- and third-stage sclerotherapy treatments scheduled within 90-day surgical global periods absent Modifier -58
How Aethera fixes it
Specialty-trained coders (CPC/CCS) code to the documentation
First-pass claim scrubbing against payer and NCCI edits
Proactive denial prevention and 72-hour denial work
Relentless A/R follow-up to drive days-in-A/R down
Eligibility and prior-auth verification before service
Transparent, real-time reporting in the provider portal
Free tools for your billing team
Use these any time — no login required.
Pediatric Vascular Malformations, Hemangiomas & Sclerotherapy billing FAQ
What is the proper coding for percutaneous sclerotherapy of pediatric venous and lymphatic malformations?
Under CPT coding guidelines, percutaneous sclerotherapy of vascular malformations is reported using CPT 37241 (vascular embolization or occlusion, venous) or CPT 49185 (sclerotherapy, fluid collection, percutaneous). Concomitant ultrasound guidance (CPT +76937-26) and fluoroscopic guidance (CPT +77002-26) are separately reportable when distinct permanent hardcopy images and written interpretation are documented. The sclerosing agent is billed separately with appropriate HCPCS J-codes and NDC numbers.
How should planned staged sclerotherapy sessions be coded during the postoperative period?
Because complex vascular anomalies typically require 2 to 4 sequential treatment sessions spaced 6 to 8 weeks apart to achieve vessel obliteration without tissue necrosis, subsequent sessions within the 90-day global period of the initial procedure must be appended with Modifier -58 (staged procedure). The initial operative report and pre-procedure clinical consultation must explicitly outline the staged treatment plan.